Wikipedia -WSS

Wikipedia

author：focus 2025-09-27 13:05:10 - browse：2

health care AI border between health care and tech — Adobe

There’s been significant investment in companies creating artificial intelligence (AI) applications for health and health care over the last decade. But while there have been successes, notably in the area of medical imaging, the industry is known more for not yet living up to its potential — think IBM Watson.

The slow pace of AI adoption in health care stems from the fact that health AI sits on the border between two large industries, health care and tech. And like the border between two nations, there are significant differences on either side.

During my career, I have spent time on each side. Now, as the CEO of a company on the border, I’ve developed a deeper understanding of the differences that create barriers to mutual innovation. For health AI to achieve its potential, health care and tech companies must keep the big picture top of mind: health care is about saving lives.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： A common UTI test for kids haunts adults as a traumatic 'nightmare'

focus

entertainment

WSS

Too many hospitalized Covid

Diverse clinical trials: Why aren’t we there yet?

Acelyrin, a rare IPO success, stumbles in its first big test

Congress considering partial increase for doctor pay in Medicare

Bernie Sanders gets little from pharma CEOs on drug prices

Having children helps parents live longer, especially after age 80

entertainment

Wikipedia

focus

Walensky prepares to leave CDC — and Congress — behind

White House touts steps to stem shortages of cancer treatments

Cancer drug shortages should be causing more outrage

Food makers to regulators: Ultra

In age of alternative facts, a scholarly course on calling out crap

How to make the FDA’s new prescription one

Tori Bowie and the unacceptable rates of Black maternal death

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Moonlake's readout produced a cash windfall. Risks remain

Long Covid needs a new name — and a new frame

knowledge

Acelyrin, a rare IPO success, stumbles in its first big test

Report cites 'urgent' need to recruit more diverse clinical trial participants

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Latigo launches with $135 million for Vertex

Long Covid needs a new name — and a new frame

entertainment

focus

entertainment

Wikipedia